Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Key Clinical Data (Authoritative Research) - Obesity: 28.7% average weight loss over 68 weeks (TRIUMPH-4 Study) - 12 mg dose: 17.5% weight loss (24w), 24.2% (48w) - Diabetes: Improves glycemic control, safety similar to GLP-1 RAs Molecular Design Highlights - GIP peptide backbone (39 amino acids), ~6-day half-life, good adherence - Special modifications: enhanced stability, long-acting, suitable for long-term use Research Focus Populations - Adults with type 2 diabetes (with diet/exercise) - Adults with obesity/overweight + weight-related comorbidities Industry Significance From single/dual-target to triple agonist, Retatrutide leads metabolic drug research, redefining diabetes/obesity research paradigms
Whether any of these compounds is right for you specifically
Why another GLP-1 blog
Murine Guanylate-binding Protein: Incomplete Geranylgeranyl Isoprenoid Modification of an Interferon--inducible Guanosine Triphosphate-binding Protein
